Resource Summary Report

Generated by dkNET on Sep 1, 2026

RWPE-1

RRID:CVCL_3791
Type: Cell Line

Proper Citation

BCRJ Cat# 0389, RRID:CVCL_3791

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3791

Proper Citation: BCRJ Cat# 0389, RRID:CVCL_3791

Description: Cell line RWPE-1 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: PMID:8977636, PMID:9214605, PMID:9214606, PMID:20215515, PMID:22275356, PMID:25877200, PMID:27397505, PMID:30305041, PMID:30787054

Comments: Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: RWPE-1

Synonyms: RWPE1

Cross References: BTO:BTO_0003709, CLO:CLO_0008905, EFO:EFO_0002323, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-3610, ATCC:CRL-3607, ATCC:CRL-11609, BCRJ:0389, BioSample:SAMN03470832, BioSample:SAMN05292437, BioSample:SAMN07709991, BioSample:SAMN07709992, BioSample:SAMN07709993, BioSample:SAMN07709994, BioSample:SAMN07709995, BioSample:SAMN07709996, BioSample:SAMN07709997, cancercelllines:CVCL_3791, CCRID:3101HUMGNHu37, CCRID:3101HUMSCSP5025, CCRID:4201HUM-CCTCC00178, CCTCC:GDC0178, Cell_Model_Passport:SIDM00020, ChEMBL-Cells:CHEMBL4295468, ChEMBL-Targets:CHEMBL4296492, CLS:305217, EGA:EGAS00001000978, ENCODE:ENCBS124FCL, ENCODE:ENCBS192LWI, ENCODE:ENCBS263AAA,

ENCODE:ENCBS875FPF, GEO:GSM827387, GEO:GSM1008595, GEO:GSM1374860, GEO:GSM1670396, IGRhCellID:RWPE1, Lonza:870, PharmacoDB:RWPE1_1336_2019, Progenetix:CVCL_3791, PubChem_Cell_line:CVCL_3791, Wikidata:Q54951497

ID: CVCL_3791

Vendor: BCRJ

Catalog Number: 0389

Record Creation Time: 20220427T221510+0000

Record Last Update: 20260829T235802+0000

Ratings and Alerts

No rating or validation information has been found for RWPE-1.

No alerts have been found for RWPE-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 738 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Macke AJ, et al. (2026) Dynamic Shifts in ER-Plasma Membrane Junctions Signaling Define Pro-Metastatic N-Glycosylation and Predict Prostate Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(30), e22885.

Fu H, et al. (2026) A smart gene circuit for precise regulation of tumor cell behavior. Synthetic and systems biotechnology, 11, 237.

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. EMBO molecular medicine, 18(5), 1967.

Yang J, et al. (2026) Astragaloside IV directly targets PPP1R14B to sensitize prostate cancer to anti-PD-1 immunotherapy by remodeling the CX3CL1/CD8+ T cell axis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158158.

Yang M, et al. (2026) MCCC2 stabilizes LTBP1 via suppressing SMURF1-dependent ubiquitination to drive bone metastasis in prostate cancer. Oncogene, 45(28), 2779.

Shi W, et al. (2026) Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer. Cancer & metabolism, 14(1).

Liu SS, et al. (2026) Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1. Acta pharmacologica Sinica, 47(6), 1643.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. iScience, 29(7), 116409.

Zheng W, et al. (2026) hsa-circKLK3-25 promotes epithelial-mesenchymal transition and malignant progression of prostate cancer through the JNK/ERK signaling pathway. American journal of cancer research, 16(3), 1081.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. Cancer gene therapy.

Zhang H, et al. (2026) ROS Cascade-Amplified Polymeric Nanosystem Exhibiting Multi-Pathway Induction of Immunogenic Cell Death and Chemotherapeutic Efficacy in Tumor. Advanced healthcare materials, 15(25), e71279.

Bernard MJ, et al. (2026) OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance. Molecular cancer research : MCR, 24(5), 356.

Kim YN, et al. (2026) Phytochemical Profiling of the Halophyte Artemisia fukudo Makino and Its In Vitro Effects on Androgen-Related Pathways Associated With Benign Prostatic Hyperplasia and Alopecia. ChemistryOpen, 15(3), e202500481.

Sekar A, et al. (2026) TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. EMBO molecular medicine, 18(6), 2062.

Luo T, et al. (2026) Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer. Advanced healthcare materials, e71387.

Alaimo A, et al. (2025) TRPM8 levels determine tumor vulnerability to channel agonists. Molecular oncology.

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. npj biological physics and mechanics, 2(1), 19.

Zhang Y, et al. (2025) Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(29), e04192.

Dathathri E, et al. (2025) PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Na??ve Prostate Cancer Patients. Cancer research communications, 5(8), 1359.

Diao Y, et al. (2025) A novel biochip-based liquid biopsy for extracellular vesicle RNA detection in prostate cancer. Cancer biology & therapy, 26(1), 2593744.